Skip to main content
. 2021 Jul 10;40(4):100931. doi: 10.1016/j.accpm.2021.100931

Table 6.

Independent risk factors associated with 28-day mortality.

OR 95% CI p-value
Model 1: Multivariate analyses of admission characteristics
Age
 < 50 years 1.0 ref _
 50–59 years 2.2 [0.8–5.7] 0.1126
 60–69 years 2.0 [0.8–5] 0.1423
 70–79 years 3.3 [1.3–8.3] 0.0113
 ≥ 80 years 9.0 [3.3–24.6] < .0001
Gender, female 1.0 [0.6–1.5] 0.8533
Body Mass Index > 40, kg.m−2 1.7 [0.8–3.7] 0.1793
COPD 1.3 [0.8–2] 0.2497
Chronic heart failure 2.4 [1.1–5] 0.0241
Chronic renal failure 2.1 [1.2–3.8] 0.0113
Cancer 1.6 [0.9–2.7] 0.0956
Arterial hypertension
 No 1.0 ref
 Yes, with treatment by ACEI or ARB 1.1 [0.7–1.7] 0.6448
 Yes, without treatment by ACEI or ARB 0.9 [0.5–1.5] 0.6103
SOFA score (without respiratory component) at inclusion
 < 2 1.0 ref
 ≥ 2 2.4 [1.6–3.7] < .0001
PaO2/FiO2
 > 200 mmHg 1.0 ref
 150−200 mmHg 1.1 [0.6–2.1] 0.8012
 100−150 mmHg 1.1 [0.7–1.9] 0.6798
 < 100 mmHg 1.8 [1.1–2.9] 0.0161
Model 2: Multivariate analysis of care at admissiona
Respiratory support
 Oxygen therapy or no ventilation 1.0 ref
 High-Flow Nasal Cannula or Non-Invasive Ventilation 0.6 [0.2–1.5] 0.2868
 Mechanical Ventilation 1.6 [0.7–3.4] 0.2756
Anticoagulants
 No anticoagulants 1.0 ref
 Prophylactic dosing 0.7 [0.4–1.4] 0.3762
 Therapeutic dosing 0.9 [0.5–1.8] 0.7503
Antiviral therapy on admission
 No antiviral therapy on admission 1.0 ref
 Antiviral therapy on admission 0.5 [0.3−0.9] 0.0194
Hydroxychloroquine on admission 1.0 [0.6–1.6] 0.9414
Corticosteroids on admission 1.0 [0.5–1.9] 0.9000

OR were calculated using random effects logistic regression. The regression was based on 908 patients for 28-day mortality.

OR: odds ratio, CI: Confidence Interval, SOFA: Sequential Organ Failure Assessment. COPD: Chronic Obstructive Pulmonary Disease, ICU: Intensive Care Unit; SOFA: Sequential Organ failure Assessment; PaO2: Oxygen Arterial Pressure; PCO2: carbon dioxide arterial pressure; COPD: chronic obstructive pulmonary disease; ACEI: angiotensin converting enzyme inhibitor, ARB: angiotensin receptor blocker.

Bold values represent statistically significant values.

a

Model 2 was adjusted for characteristics at admission.